Effective Dosage and Administration Schedule of Oral Alendronate for Non-nociceptive Symptoms in Rats with Chronic Constriction Injury

다국어 초록 (Multilingual Abstract)

We evaluated the efficacy of oral alendronate with different dosing regimens for nonnociceptive symptoms and osteoporosis in a sciatic nerve chronic constriction injury (CCI) model. Male Sprague-Dawley rats (n=60) were subdivided into sham control (SC) group and CCI groups, which were divided according to dosage and time of oral alendronate administration: no treatment (NT), low dosage early (LE), high dosage early (HE), low dosage late (LL) and high dosage late (HL). We measured the thickness and temperature of the hind paw, bone mineral density (BMD) of the tibia, along with tibia bone strength. On the 14th day post-CCI, the HE group showed significant reduction in thickness and temperature (P<0.001). On the 42nd day post-CCI, the HE group showed significant reduction in temperature compared to the NT group (P<0.001). Also, both HE and HL groups showed statistically significant increased tibia BMD (P<0.001), along with increase of tibia bone strength compared to the NT group. Based on these findings, early alendronate in high dosages is effective in the non-nociceptive symptoms; early and late alendronate in high dosages,are effective in preventing bone dystrophic changes in a CCI model.

참고문헌 (Reference)

1 Burr DB, "Tissue mineralization is increased following 1-yr treatment with high doses of bisphosphonates in dogs" 33 : 960-969, 2003

2 Mashiba T, "Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib" 15 : 613-620, 2000

3 Guo TZ, "Substance P signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture rat model of complex regional pain syndrome type I" 108 : 95-107, 2004

4 van der Laan L, "Severe complications of reflex sympathetic dystrophy: infection, ulcers, chronic edema, dystonia, and myoclonus" 79 : 424-429, 1998

5 Manicourt DH, "Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity" 50 : 3690-3697, 2004

6 Rodan GA, "Preclinical pharmacology of alendronate" 3 (3): 7-12, 1993

7 Poplawski ZJ, "Post-traumatic dystrophy of the extremities" 65 : 642-655, 1983

8 Mackey S, "Pharmacologic therapies for complex regional pain syndrome" 11 : 38-43, 2007

9 Birklein F, "Pattern of autonomic dysfunction in time course of complex regional pain syndrome" 8 : 79-85, 1998

10 Suyama H, "Osteoporosis following chronic constriction injury of sciatic nerve in rats" 20 : 91-97, 2002

11 Huygen FJ, "Neuroimmune alterations in the complex regional pain syndrome" 429 : 101-113, 2001

12 Daemen MA, "Neurogenic inflammation in an animal model of neuropathic pain" 20 : 41-45, 1998

13 Daemen M, "Neurogenic inflammation and reflex sympathetic dystrophy (in vivo and in vitro assessment in an experimental model)" 64 : 441-447, 1998

14 Varenna M, "Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study" 27 : 1477-1483, 2000

15 Schinkel C, "Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome" 22 : 235-239, 2006

16 Guo TZ, "Glucocorticoid inhibition of vascular abnormalities in a tibia fracture rat model of complex regional pain syndrome type I" 121 : 158-167, 2006

17 Kingery WS, "Glucocorticoid inhibition of neuropathic limb edema and cutaneous neurogenic extravasation" 913 : 140-148, 2001

18 Robinson JN, "Efficacy of pamidronate in complex regional pain syndrome type I" 5 : 276-280, 2004

19 Bianchi M, "Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain" 12 : 284-292, 2008

20 Griffin MG, "Dual-energy x-ray absorptiometry of the rat: accuracy, precision, and measurement of bone loss" 8 : 795-800, 1993

21 Janig W, "Complex regional pain syndrome: mystery explained?" 2 : 687-697, 2003

22 Coderre TJ, "Chronic post-ischemia pain (CPIP): a novel animal model of complex regional pain syndrome- type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat" 112 : 94-105, 2004

23 Lee JI, "Changes in bone metabolism in a rat model of traumatic brain injury" 19 : 1207-1211, 2005

24 Adami S, "Bisphosphonate therapy of reflex sympathetic dystrophy syndrome" 56 : 201-204, 1997

25 Bonabello A, "Analgesic effect of bisphosphonates in mice" 91 : 269-275, 2001

26 Breuer B, "An openlabel pilot trial of ibandronate for complex regional pain syndrome" 24 : 685-689, 2008

27 Goicoechea C, "Alendronate induces antinociception in mice, not related with its effects in bone" 79 : 433-437, 1999

28 Kingery WS, "A substance P receptor (NK1) antagonist enhances the widespread osteoporotic effects of sciatic nerve section" 33 : 927-936, 2003

29 Bennett GJ, "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man" 33 : 87-107, 1988

30 Kingery WS, "A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes" 73 : 123-139, 1997